114 related articles for article (PubMed ID: 2438800)
21. A battery of monoclonal antibodies that induce unique conformations to evolve cryptic but constitutive functions of plasminogen.
Madoiwa S; Arai K; Ueda Y; Ishizuka M; Mimuro J; Asakura S; Matsuda M; Sakata Y
J Biochem; 1997 Feb; 121(2):278-87. PubMed ID: 9089401
[TBL] [Abstract][Full Text] [Related]
22. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
Thorsen S; Müllertz S; Suenson E; Kok P
Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
[TBL] [Abstract][Full Text] [Related]
23. Interaction of staphylokinase with different molecular forms of plasminogen.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1993 Jan; 211(1-2):91-7. PubMed ID: 8425556
[TBL] [Abstract][Full Text] [Related]
24. [Features of the interaction between alpha2-antiplasmin and plasminogen/plasmin].
Hrynenko TV; Iusova OI; Zadorozhna MB; Makohonenko IeM
Ukr Biokhim Zh (1999); 2002; 74(6):83-90. PubMed ID: 12924019
[TBL] [Abstract][Full Text] [Related]
25. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
[TBL] [Abstract][Full Text] [Related]
26. [Binding of alpha-2-antiplasmin with fibrinogen/fibrin and their fragments independent of factor XIII].
Zadorozhna MB; Hrynenko TV; Iusova OI; Volkov HL
Ukr Biokhim Zh (1999); 2004; 76(5):71-7. PubMed ID: 16100900
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.
Angles-Cano E; Rouy D; Lijnen HR
Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies detect receptor-induced binding sites in Glu-plasminogen.
Han J; Baik N; Kim KH; Yang JM; Han GW; Gong Y; Jardí M; Castellino FJ; Felez J; Parmer RJ; Miles LA
Blood; 2011 Aug; 118(6):1653-62. PubMed ID: 21680799
[TBL] [Abstract][Full Text] [Related]
29. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop.
Stigbrand T; Andrés C; Bellanger L; Bishr Omary M; Bodenmüller H; Bonfrer H; Brundell J; Einarsson R; Erlandsson A; Johansson A; Leca JF; Levi M; Meier T; Nap M; Nustad K; Seguin P; Sjödin A; Sundström B; van Dalen A; Wiebelhaus E; Wiklund B; Arlestig L; Hilgers J
Tumour Biol; 1998; 19(2):132-52. PubMed ID: 9486565
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of the process of Glu-plasminogen activation by tissue activator with fibrin, DDE-complex, and D-dimer using alpha-2-antiplasmin].
Hrynenko TV; Zadorozhna MB; Platonova TM; Volkov HL
Ukr Biokhim Zh (1999); 2005; 77(5):45-51. PubMed ID: 16846069
[TBL] [Abstract][Full Text] [Related]
31. Immunochemical characterization of the kringle 4 fragment of human plasminogen.
Hochschwender SM; Laursen RA
J Biol Chem; 1981 Nov; 256(21):11166-71. PubMed ID: 7287760
[TBL] [Abstract][Full Text] [Related]
32. Purification of human alpha 2-plasmin inhibitor using monoclonal antibody column chromatography.
Sumi Y; Koike Y; Ichikawa Y; Aoki N
J Biochem; 1989 Aug; 106(2):192-3. PubMed ID: 2808315
[TBL] [Abstract][Full Text] [Related]
33. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
[TBL] [Abstract][Full Text] [Related]
34. Topography of the high-affinity lysine binding site of plasminogen as defined with a specific antibody probe.
Miles LA; Plow EF
Biochemistry; 1986 Nov; 25(22):6926-33. PubMed ID: 3099830
[TBL] [Abstract][Full Text] [Related]
35. On the localization of the cleavage site in human alpha-2-antiplasmin, involved in the generation of the non-plasminogen binding form.
Abdul S; Dekkers DHW; Ariëns RAS; Leebeek FWG; Rijken DC; Uitte de Willige S
J Thromb Haemost; 2020 May; 18(5):1162-1170. PubMed ID: 32034861
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies inhibitory to human plasmin. Definitive demonstration of a role for plasmin in activating the proenzyme of urokinase-type plasminogen activator.
Sim PS; Fayle DR; Doe WF; Stephens RW
Eur J Biochem; 1986 Aug; 158(3):537-42. PubMed ID: 2942403
[TBL] [Abstract][Full Text] [Related]
37. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen.
Wiman B; Lijnen HR; Collen D
Biochim Biophys Acta; 1979 Jul; 579(1):142-54. PubMed ID: 157166
[TBL] [Abstract][Full Text] [Related]
38. [Modifying effect of antiplasminogen monoclonal antibody IV-1c on human plasmin catalytic properties].
Grinenko TV; Makogonenko EM; Iusova EI; Skomorovskaia-Prokvolit EV; Cederholm-Williams SA; Kolesnikova IN
Ukr Biokhim Zh (1999); 2002; 74(4):61-70. PubMed ID: 14964863
[TBL] [Abstract][Full Text] [Related]
39. Production and characterization of specific bovine plasminogen monoclonal antibodies.
Dupont D; Labiau S; Grosclaude J; Collin JC
Hybridoma; 1994 Dec; 13(6):543-7. PubMed ID: 7737679
[TBL] [Abstract][Full Text] [Related]
40. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.
Rijken DC; Groeneveld E; Kluft C; Nieuwenhuis HK
Biochem J; 1988 Oct; 255(2):609-15. PubMed ID: 2974279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
